Literature DB >> 20228162

Infants of women with polycystic ovary syndrome have lower cord blood androstenedione and estradiol levels.

Helen Anderson1, Naomi Fogel, Stefan K Grebe, Ravinder J Singh, Robert L Taylor, Andrea Dunaif.   

Abstract

CONTEXT: Prenatal androgen excess can cause a phenocopy of polycystic ovary syndrome (PCOS) in mammals. Retrospective studies have suggested that girls at risk for PCOS have low birth weight, and prospective studies have suggested an increased prevalence of small-for-gestational-age offspring in women with PCOS.
OBJECTIVE: The objective of the study was to determine whether infants of women with PCOS have reduced birth weight or increased intrauterine androgen levels.
DESIGN: This was a prospective case-control study. PARTICIPANTS: Thirty-nine PCOS and 31 control women and their infants participated in the study. MAIN OUTCOME MEASURES: Birth weight and mixed cord blood testosterone, androstenedione (A), dehydroepiandrosterone, 17-hydroxyprogesterone, estradiol (E2), and dihydrotestosterone levels were measured.
RESULTS: Mean birth weight did not differ, but there was a significant increase in the prevalence of large-for-gestational-age infants in the PCOS group. Cord blood E2 and A levels were lower (P < 0.05), but testosterone to E2 ratios did not differ in female PCOS compared with control offspring. There was no difference in E2 and A levels in the male PCOS and control offspring. There was no difference in 17-hydroxyprogesterone or other androgen levels in either male or female PCOS offspring compared with their respective control group.
CONCLUSION: Infants of women with PCOS were more likely to be large for gestational age. Female offspring of affected women have lower cord blood A levels; other cord blood androgen levels do not differ compared with female control offspring. Cord blood E2 levels are also significantly decreased in PCOS, without any difference in the testosterone to E2 ratio, suggesting decreased fetal or placental production of steroids.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20228162      PMCID: PMC2869542          DOI: 10.1210/jc.2009-2651

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  40 in total

1.  Early puberty-menarche after precocious pubarche: relation to prenatal growth.

Authors:  Lourdes Ibáñez; Rafael Jiménez; Francis de Zegher
Journal:  Pediatrics       Date:  2006-01       Impact factor: 7.124

Review 2.  A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome.

Authors:  C M Boomsma; M J C Eijkemans; E G Hughes; G H A Visser; B C J M Fauser; N S Macklon
Journal:  Hum Reprod Update       Date:  2006-08-04       Impact factor: 15.610

3.  Polycystic ovaries after precocious pubarche: relation to prenatal growth.

Authors:  L Ibáñez; A Jaramillo; G Enríquez; E Miró; A López-Bermejo; D Dunger; F de Zegher
Journal:  Hum Reprod       Date:  2006-10-24       Impact factor: 6.918

4.  Human fetal ovary development involves the spatiotemporal expression of p450c17 protein.

Authors:  Beth Cole; Krista Hensinger; Gustavo A R Maciel; R Jeffery Chang; Gregory F Erickson
Journal:  J Clin Endocrinol Metab       Date:  2006-07-05       Impact factor: 5.958

5.  Birth weight in offspring of mothers with polycystic ovarian syndrome.

Authors:  Teresa Sir-Petermann; Catalina Hitchsfeld; Manuel Maliqueo; Ethel Codner; Bárbara Echiburú; Raimundo Gazitúa; Sergio Recabarren; Fernando Cassorla
Journal:  Hum Reprod       Date:  2005-03-31       Impact factor: 6.918

6.  Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance.

Authors:  Andrea D Coviello; Richard S Legro; Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2005-10-25       Impact factor: 5.958

Review 7.  Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?

Authors:  D H Abbott; D K Barnett; C M Bruns; D A Dumesic
Journal:  Hum Reprod Update       Date:  2005 Jul-Aug       Impact factor: 15.610

8.  Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.

Authors:  Alessandra Gambineri; Laura Patton; Antonella Vaccina; Mauro Cacciari; Antonio Maria Morselli-Labate; Carla Cavazza; Uberto Pagotto; Renato Pasquali
Journal:  J Clin Endocrinol Metab       Date:  2006-07-25       Impact factor: 5.958

9.  Relationships between sex hormones assessed in amniotic fluid, and maternal and umbilical cord serum: what is the best source of information to investigate the effects of fetal hormonal exposure?

Authors:  Cornelieke van de Beek; Jos H H Thijssen; Peggy T Cohen-Kettenis; Stephanie H M van Goozen; Jan K Buitelaar
Journal:  Horm Behav       Date:  2004-12       Impact factor: 3.587

10.  Associations of birthweight and gestational age with reproductive and metabolic phenotypes in women with polycystic ovarian syndrome and their first-degree relatives.

Authors:  Richard S Legro; Rebecca L Roller; William C Dodson; Christina M Stetter; Allen R Kunselman; Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

View more
  52 in total

Review 1.  Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome.

Authors:  Selma F Witchel; Sergio E Recabarren; Frank González; Evanthia Diamanti-Kandarakis; Kai I Cheang; Antoni J Duleba; Richard S Legro; Roy Homburg; Renato Pasquali; Rogerio A Lobo; Christos C Zouboulis; Fahrettin Kelestimur; Franca Fruzzetti; Walter Futterweit; Robert J Norman; David H Abbott
Journal:  Endocrine       Date:  2012-06-04       Impact factor: 3.633

2.  Female Offspring From Chronic Hyperandrogenemic Dams Exhibit Delayed Puberty and Impaired Ovarian Reserve.

Authors:  Zhiqiang Wang; Mingjie Shen; Ping Xue; Sara A DiVall; James Segars; Sheng Wu
Journal:  Endocrinology       Date:  2018-02-01       Impact factor: 4.736

3.  Perspectives in Polycystic Ovary Syndrome: From Hair to Eternity.

Authors:  Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2016-02-23       Impact factor: 5.958

Review 4.  Hyperandrogenic origins of polycystic ovary syndrome - implications for pathophysiology and therapy.

Authors:  David H Abbott; Daniel A Dumesic; Jon E Levine
Journal:  Expert Rev Endocrinol Metab       Date:  2019-02-15

Review 5.  Ontogeny of polycystic ovary syndrome and insulin resistance in utero and early childhood.

Authors:  David H Abbott; Fida Bacha
Journal:  Fertil Steril       Date:  2013-07       Impact factor: 7.329

Review 6.  Mechanisms of intergenerational transmission of polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Luis R Hoyos; Gregorio D Chazenbalk; Rajanigandha Naik; Vasantha Padmanabhan; David H Abbott
Journal:  Reproduction       Date:  2020-01       Impact factor: 3.906

Review 7.  Gestational Hyperandrogenism in Developmental Programming.

Authors:  Christopher Hakim; Vasantha Padmanabhan; Arpita K Vyas
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

Review 8.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

9.  Early embryonic androgen exposure induces transgenerational epigenetic and metabolic changes.

Authors:  Ning Xu; Angela K Chua; Hong Jiang; Ning-Ai Liu; Mark O Goodarzi
Journal:  Mol Endocrinol       Date:  2014-07-03

Review 10.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.